Odanacatib: A review of its potential in the management of osteoporosis in postmenopausal women

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 3, 2015, Pages 103-109

  Chapurlat, Roland D ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

cathepsin K; fracture; odanacatib; osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CREATININE; ODANACATIB; PLACEBO;

BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL THICKNESS (BONE); DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; FRAGILITY FRACTURE; HIP; HUMAN; LUMBAR SPINE; MORPHEA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PHARMACOKINETIC ASSAY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIBIA; TREATMENT OUTCOME;

EID: 84930516774     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X15580903     Document Type: Review

References (43)

1. Barrett D. Boncek V. Catalano J. Deaton D. Hassell A. Jurgensen C. et al. (2005) P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg. Med Chem Lett 15: 3540–3546.
2. Black D. Cummings S. Karpf D. Cauley J. Thompson D. Nevitt M. et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
3. Black D. Delmas P. Eastell R. Reid I. Boonen S. Cauley J. et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
4. Bliuc D. Nguyen N. Milch V. Nguyen T. Eisman J. (2009) Mortality risk associated with low trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513–521.
5. Bone H. McClung M. Roux C. Recker R. Eisman J. Verbruggen N. et al. (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25: 937–947.
6. Bonnick S. de Villiers T. Odio A. Palacios S. Chapurlat R. DaSilva C. et al. (2013) Effects of Odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate – a randomized placebo-controlled trial. J Clin Endocrinol Metab 98: 4727–4735.
7. Brixen K. Chapurlat R. Cheung A. Keaveny T. Fuerst T. Engelke K. et al. (2013) Bone Density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98: 571–580.
8. Cabal A. Jayakar R. Sardesai S. Phillips E. Szumiloski J. Posavec D. et al. (2013) High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone 56: 497–505.
9. Chapurlat R. (2013) Contributions and limitations of the FRAX tool. Joint Bone Spine 80: 355–357.
10. Chavassieux P. Asser Karsdal M. Segovia-Silvestre T. Neutzsky-Wulff A. Chapurlat R. et al. (2008) Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23: 1076–1083.
11. Chesnut C. III Skag A. Christiansen C. Recker R. Stakkestad J. Hoiseth A. et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249.
12. Cheung A. Majumdar S. Brixen K. Chapurlat R. Fuerst T. Engelke K. et al. (2014) Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry and estimated bone strength. J Bone Miner Res 29: 1786–1794.
13. Cummings S. Black D. Thompson D. Applegate W. Barrett-Connor E. Musliner T. et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077–2082.
14. Cummings S. San Martin J. McClung M. Siris E. Eastell R. Reid I. et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765.
15. Cusick T. Chen C. Pennypacker B. Pickarski M. Kimmel D. Scott B. et al. (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Min Res 27: 524–537.
16. Delmas P. Ensrud K. Adachi J. Harper K. Sarkar S. Gennari C. et al. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87: 3609–3617.
17. Duong L. (2012) Therapeutic inhibition of cathepsin K – reducing bone resorption while maintaining bon formation. BoneKEy Rep 1: 67.
18. Eisman J. Bone H. Hosking D. McClung M. Reid I. Rizzoli R. et al. (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26: 242–251.
19. Engelke K. Fuerst T. Dardzinski B. Kornak J. Ather S. Genant H. de Papp A. (2015) Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women - results of a 2-year placebo-controlled trial. J Bone Miner Res 30: 30–38.
20. Everts V. Aronson D. Beertsen W. (1985) Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 37: 25–31.
21. Fuller K. Lindstrom E. Edlund M. Henderson I. Grabowska U. Szewczyk K. et al. (2010) The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K. Bone 46: 1400–1407.
22. Greenspan S. Bone H. Ettinger M. Hanley D. Lindsay R. Zanchetta J. et al. (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Int Med 146: 326–339.
23. Harris S. Watts N. Genant H. McKeever C. Hangartner T. Keller M. et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352.
24. Kanis J. Svedbom A. Harvey N. McCloskey E. (2014) The osteoporosis treatment gap. J Bone Miner Res 29: 1926–1928.
25. Kassahun K. Black W. Nicoll-Griffith D. McIntosh I. Chauret N. Day S. et al. (2011) Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. DMD 39: 1079–1087.
26. Kumar S. Dare L. Vasko-Moser J. James I. Blake S. Rickard D. et al. (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40: 122–131.
27. Langdahl B. Binkley N. Bone H. Gilchrist N. Resch H. Rodriguez Portales J. et al. (2013) Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res 27: 2251–2258.
28. Leung P. Pickarski M. Zhuo Y. Masarachia P. Duong L. (2011) The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking Bone 49: 623–635.
29. Li C. Jepsen K. Majeska R. Zhang J. Ni R. Gelb B. et al. (2006) Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21: 865–875.
30. Lotinun S. Kiviranta R. Matsubara T. Alzate J. Neff L. Luth A. et al. (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation J Clin Invest 123: 666–681.
31. Masarachia P. Pennypacker B. Pickarski M. Scott K. Wesolowski G. Smith S. et al. (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27: 509–523.
32. McClung M. Geusens P. Miller P. Zippel H. Bensen W. Roux C. et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333–340.
33. Meunier P. Roux C. Seeman E. Ortolani S. Badurski J. Spector T. et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–468.
34. Neer R. Arnaud C. Zanchetta J. Prince R. Gaich G. Reginster J. et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
35. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785–795.
36. Omsland T. Magnus J. (2014) Forecasting the burden of future postmenopausal hip fractures. Osteoporos Int 25: 2493–2496.
37. Pennypacker B. Shea M. Liu Q. Masarachia P. Saftig P. Rodan S. et al. (2009) Bone density, strength, and formation in adult cathepsin K (−/−) mice. Bone 44: 199–207.
38. Pennypacker B. Le Duong T. Cusick T. Masarachia P. Gentile M. Gauthier J. et al. (2011) Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 26: 252–262.
39. Reginster J. Seeman E. de Vernejoul M. Adami S. Compston J. Phenekos C. et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90: 2816–2822.
40. Solomon D. Johnston S. Boytsov N. McMorrow D. Lane J. Krohn K. (2014) Osteoporosis medication use after hip fracture in US patients between 2002 and 2011 J Bone Miner Res 29: 1929–1937.
41. Stoch S. Zajic S. Stone J. Miller F. van Dick K. Guttierez M. et al. (2009) Effect of the cathepsin k inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86: 175–182.
42. Williams D. McCracken P. Purcell M. Pickarski M. Mathers P. Savitz A. et al. (2013) Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 56: 489–496.
43. Zhuo Y. Gauthier J. Black W. Percival M. Duong L. (2014) Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone 67: 269–280.